These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28985058)

  • 1. Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease.
    Fiorito J; Vendome J; Saeed F; Staniszewski A; Zhang H; Yan S; Deng SX; Arancio O; Landry DW
    J Med Chem; 2017 Nov; 60(21):8858-8875. PubMed ID: 28985058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
    Fiorito J; Saeed F; Zhang H; Staniszewski A; Feng Y; Francis YI; Rao S; Thakkar DM; Deng SX; Landry DW; Arancio O
    Eur J Med Chem; 2013 Feb; 60():285-94. PubMed ID: 23313637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
    Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
    Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity.
    Zuccarello E; Zhang H; Acquarone E; Pham D; Staniszewski A; Deng SX; Landry DW; Arancio O; Fiorito J
    Bioorg Med Chem Lett; 2023 Aug; 92():129409. PubMed ID: 37453616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.
    Zhang L; Seo JH; Li H; Nam G; Yang HO
    Br J Pharmacol; 2018 Aug; 175(16):3347-3360. PubMed ID: 29847860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
    Liu L; Xu H; Ding S; Wang D; Song G; Huang X
    Brain Res Bull; 2019 Nov; 153():223-231. PubMed ID: 31493542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.
    Puzzo D; Staniszewski A; Deng SX; Privitera L; Leznik E; Liu S; Zhang H; Feng Y; Palmeri A; Landry DW; Arancio O
    J Neurosci; 2009 Jun; 29(25):8075-86. PubMed ID: 19553447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.
    Kang BW; Kim F; Cho JY; Kim S; Rhee J; Choung JJ
    Alzheimers Res Ther; 2022 Jul; 14(1):92. PubMed ID: 35804462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    J Med Chem; 2016 Oct; 59(19):8967-9004. PubMed ID: 27606546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
    Di Pietro O; Pérez-Areales FJ; Juárez-Jiménez J; Espargaró A; Clos MV; Pérez B; Lavilla R; Sabaté R; Luque FJ; Muñoz-Torrero D
    Eur J Med Chem; 2014 Sep; 84():107-17. PubMed ID: 25016233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
    Jin F; Gong QH; Xu YS; Wang LN; Jin H; Li F; Li LS; Ma YM; Shi JS
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):871-81. PubMed ID: 24513083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
    Huang XF; Dong YH; Wang JH; Ke HM; Song GQ; Xu DF
    Bioorg Med Chem Lett; 2020 May; 30(9):127097. PubMed ID: 32171616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modelling, synthesis and acetylcholinesterase inhibition of ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridine-3-carboxylate.
    Soriano E; Samadi A; Chioua M; de los Ríos C; Marco-Contelles J
    Bioorg Med Chem Lett; 2010 May; 20(9):2950-3. PubMed ID: 20350807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors.
    Ahmed NS; Gary BD; Tinsley HN; Piazza GA; Laufer S; Abadi AH
    Arch Pharm (Weinheim); 2011 Mar; 344(3):149-57. PubMed ID: 21384413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Fujishige K; Takagi M; Kikkawa K; Omori K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2341-5. PubMed ID: 12824030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.
    Zhang P; Jiang MY; Le ML; Zhang B; Zhou Q; Wu Y; Zhang C; Luo HB
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127254. PubMed ID: 32527553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
    Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
    Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and experimental confirmation of novel cGMP efflux inhibitors by virtual ligand screening of vardenafil-analogues.
    Kashgari FK; Ravna A; Sager G; Lyså R; Enyedy I; Dietrichs ES
    Biomed Pharmacother; 2020 Jun; 126():110109. PubMed ID: 32229414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.